Keyphrases
Radionuclide Generator
100%
Pancreatic Cancer
66%
Targeted Therapy
66%
Radioimmunotherapy
44%
Intranuclear
33%
Histone
27%
Intracellular Antigens
25%
Zevalin
16%
Systemic Treatment
11%
Target Antigen
11%
Alpha Particles
11%
Radiolabeled Antibody
11%
Radionuclides
11%
212Pb
11%
Tumor Cells
11%
212Bi
11%
Tumor
11%
Surface Antigen
11%
Monoclonal Antibody
11%
Specific Monoclonal Antibodies
11%
Antibody Binding
11%
Physical Destruction
8%
Bexxar
8%
In Vivo Generator
8%
Multidrug Resistance Mechanism
8%
Sequential Lymphoma
8%
Low Toxicity
5%
Cytocidal
5%
CD20
5%
Refractory Lymphoma
5%
Lead-212
5%
Melanin pigment
5%
Healthy Tissue
5%
Metastatic Melanoma
5%
Fast-growing
5%
Resectable Pancreatic Cancer
5%
Cisplatin
5%
Tumoricidal Activity
5%
Poor Prognosis
5%
Cancer Targeting
5%
Therapeutic Modalities
5%
Bismuth
5%
Pre-treating
5%
Particulate
5%
First-line Therapy
5%
Growing Tumor
5%
Cell Turnover
5%
Sustained Response
5%
Effective Method
5%
Clinical Trials
5%
Alpha Radiation
5%
Public Health
5%
Melanin Binding
5%
Tumor Uptake
5%
High Specificity
5%
Conventional Chemotherapy
5%
Beta Radiation
5%
Cross-reactivity
5%
Newly Diagnosed Patients
5%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
5%
Non-Hodgkin Lymphoma
5%
Gemcitabine
5%
Medicine and Dentistry
Pancreas Cancer
66%
Targeted Therapy
66%
Radioisotope
66%
Radioimmunotherapy
41%
Monoclonal Antibody
30%
Histone
25%
Neoplasm
20%
Ibritumomab Tiuxetan
15%
Lead 212
15%
Melanin
10%
Membrane Antigen
10%
Tumor Cell
10%
Systemic Therapy
10%
Bismuth 212
10%
Tositumomab I 131
7%
Patient with Non-Hodgkins Lymphoma
5%
CD20
5%
Cross Reaction
5%
Therapeutic Modality
5%
Gemcitabine
5%
Cisplatin
5%
Clinical Trial
5%
Malignant Neoplasm
5%
Antigen Binding
5%
Side Effect
5%
Chemotherapy
5%
Multidrug Resistance
5%
Metastatic Melanoma
5%
Lung Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
66%
Radioisotope
66%
Neoplasm
30%
Monoclonal Antibody
30%
Histone
25%
Ibritumomab Tiuxetan
15%
Lead 212
15%
Melanin
10%
Membrane Antigen
10%
Bismuth 212
10%
Systemic Treatment
10%
Tositumomab I 131
7%
Malignant Neoplasm
5%
Gemcitabine
5%
Metastatic Melanoma
5%
Clinical Trial
5%
Lung Cancer
5%
Side Effect
5%
Cisplatin
5%
Multiple Drug Resistance
5%
Nonhodgkin Lymphoma
5%
Chemotherapy
5%